Coronary RevascUlarIzation in Patients With End-StagE Renal Disease on Dialysis in China-Retrospective Registry
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,249
- 试验地点
- 1
- 主要终点
- All-cause death
研究概览
简要总结
Coronary artery disease (CAD) is the leading cause of death in end-stage renal disease (ESRD) patients requiring dialysis. There are limited data on clinical characteristics, treatment strategies and outcomes in this special patient population in China. As a nationwide, observational, multicenter cohort study, this study consecutively included ESRD patients on dialysis with significant CAD at 30 tertiary care centers in 12 provinces in China from January 2015 to June 2021. Patient data collected included demographics, comorbidities, cardiac history, cardiac function, location and severity of CAD, procedural information, medications, and clinical events.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •50% or greater stenosis in any of three main coronary arteries or left main coronary artery on visual assessment of the coronary angiogram
- •Receive peritoneal dialysis or hemodialysis for more than 3 months
排除标准
- 未提供
结局指标
主要结局
All-cause death
时间窗: 12-month follow-up
All-cause deaths include cardiovascular death and non-cardiovascular death. Cardiovascular death is defined as death due to acute myocardial infarction, heart failure, sudden cardiac death, stroke, cardiovascular procedure, or cardiovascular hemorrhage. Non-cardiovascular death: any death not covered by the above definitions, such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide, or trauma.
次要结局
- Cardiovascular death(From the hospital admission to 12-month follow-up)
- Non-fatal myocardial infarction(From the hospital admission to 12-month follow-up)
- Major or clinically relevant nonmajor bleeding(From the hospital admission to 12-month follow-up)
- Clinically relevant nonmajor bleeding(From the hospital admission to 12-month follow-up)
- Major adverse cardiovascular events(From the hospital admission to 12-month follow-up)
- Major bleeding(From the hospital admission to 12-month follow-up)
- Non-fatal myocardial stroke(From the hospital admission to 12-month follow-up)
- Follow-up major adverse cardiovascular and clinical events(From the hospital admission, and up to 10 years)
研究者
Jingang Zheng
Head of Cardiology
China-Japan Friendship Hospital